The influence of TURBT on staging of bladder cancer

Abstract

Introduction: Bladder cancer is common, expensive and the number of cases rising with increased survival in the elderly population. Most centres do CT scan at the point of investigation and some will carry this out along with MRI scan to have better local staging once the diagnosis of invasive cancer is made. Any surgical procedure would have a likelihood of influencing local staging and this is a common belief without any evidence.

Methods: We have retrospectively analyzed our data to see where the truth lies. We have compared the final pathology of 236 radical cystectomy patients to the staging reports of 241 CT scans and 65 MRI scans.

Results: We have ascertained accuracy, sensitivity and specificity and whether they were influenced by the timing of the TURBT. There was no significant difference between CT and MRI and the timing of the TURBT.

Conclusion: This is the first report in the literature outlining the non-influence of TURBT. We accept the limitation due to the retrospective nature, small sample size and variability of the biology of bladder cancer.

Keywords: bladder cancer, staging, MRI, CT, TURBT

Introduction

Bladder cancer is a common worldwide problem. It is expensive and fraught with problems regarding optimal staging and management. The vast majority are transitional cell cancers and 70% present as superficial disease with a very low chance of metastasis and 30% present as muscle invasive with a high risk of death from distant metastases. Metastases develop in 25% of muscle invasive tumors and 50% of tumors invading the perivesical fat. Neo adjuvant and adjuvant chemotherapy regimens may improve the outcome for muscle invasive disease and metastatic disease. However, the consensus is that MRI is superior to CT for T staging. MRI imaging is considered superior to CT for T staging because of its intrinsic high soft tissue contrast, sub millimeter spatial resolution and direct multi planar imaging capabilities to determine depth of invasion. However, there is a chemical shift artifact from differences in the resonance frequencies of protons in water and fat causing bright and black bands along interfaces with bladder wall and this can impair the identification of cancer.

DWI is better than conventional MRI for T staging particularly differentiating T1 from T2 and higher. ADC can also predict grade. The greatest problem for all methods is over staging and dynamic MRI is no exception. However, the potential superiority of MRI is further strengthened as DWI differentiates metastatic nodes from non involved nodes and has good reproducibility amongst radiologist. Tumor size and ADC can determine both stage and grade. DCE can distinguish between residual tumor and neo adjuvant chemotherapy effects. However, despite apparent advantages, there remains the problem of over staging the most frequent and longstanding error. This is due to a partial volume effect at tumor-wall interface, a thin bladder makes differentiation of muscle layers intrinsically difficult and can also due to overt staging.

Further, perivesical inflammation in part due to intra vesical medication and TURBT can cause prolonged nonspecific thickening of the bladder and are difficult to distinguish from tumor on imaging. Intra luminal clot and stones can also cause false positives. In addition, staging mistakes occur as MRI can understate as we see that 30% of MIBC are initially diagnosed as NMIBC. This is due to chemical shift artifact and microscopic invasion into muscle or fat or adjacent organs. TURBT is problematic as it can seed tumor cells. Further, it delays radical treatment in MIBC and One would like to separate superficial from invasive tumors at diagnosis. This could save time, costs and improve outcomes. We have tried to elucidate whether a TURBT before imaging is more accurate than imaging after TURBT which is described as being confounded by staging errors (Table 1).
The influence of TURBT on staging of bladder cancer

Table 1 TNM stage classification of bladder cancer

| Stage | Definition |
|-------|------------|
| Tx    | Primary tumour cannot be assessed; information not known |
| T0    | No evidence of primary tumour |
| Ta    | Non invasive papillary carcinoma |
| Tis   | Non invasive flat carcinoma, also called flat carcinoma in situ. This means that the disease is still localized, or contained within the urothelium layer of the bladder wall. Cancer cells have not invaded the deeper layers of bladder wall tissue. |
| T1    | The tumour has grown from the layer of cells lining the bladder into the connective tissue below. It has not grown into the muscle layer of the bladder. |
| T2    | Tumour has grown into the muscle layer |
| T2a   | The tumour is in the inner half of the muscle layer |
| T2b   | The tumour is in the outer half of the muscle layer |
| T3    | Tumour has grown through the muscle layer and into the surrounding fatty tissue |
| T3a   | This spread into the fatty tissue can only be seen with a microscope |
| T3b   | This spread into the fatty tissue is large enough to be seen on imaging test or to be seen/felt by the surgeon |
| T4    | Tumour has spread into nearby organs or structures. It may be growing in the stroma (main tissue) of the prostate, the seminal vesicles, uterus, vagina, pelvic wall or abdominal wall |
| Nx    | Nearby lymph nodes cannot be assessed; information not known |
| N0    | The cancer has not spread to any nearby lymph nodes |
| N1    | The cancer has spread to one lymph node in the true pelvis |
| N2    | The cancer has spread to two or more lymph nodes in the true pelvis |
| N3    | The cancer has spread to lymph nodes that lie along the common iliac artery |
| M0    | No distant spread |
| M1    | The cancer has spread to distant sites outside the bladder region (for example, the lungs, liver or bones) |

Methods

We retrospectively assessed 236 sequential radical cystectomy patients at a single centre (Frimley Healthcare Foundation Trust), a district general hospital. The records of imaging, pathology and operations were all electronically stored on PACS, ICE and master lab, and IQutopia systems. The operations were done by a single surgeon (HM) over a 14 year period 1999-2014. We compared the final pathological stage (stained with haematoxylin-eosin by a pathologist) with the radiological stage for both CT and MRI. We were able to compare 241 CT scans and 65 MRI scans reported by an experienced radiologist. Imaging was then stratified by whether it was performed before or after TURBT. We then compared both modalities before and after TURBT with regard to staging accuracy. This was divided into superficial NMIBC pT1 and muscle invasive MIBC pT2 and higher. The NMIBC patients represent patients with primary NMIBC and failed intra vesical chemotherapy regimens and are thus a selected population. We documented the timing of the TURBT, before or after the scan Statistics Medcalc software was used. Sensitivity, specificity, positive and negative predictive values were done to gauge the approximate accuracy and clinical trends in imaging along with Cohen’s Kappa test which measures inter observer (imaging modality) agreement. This accounts for the possibility of agreement by chance.

Table 2 The detection of muscle invasive (T2,3,4) from superficial (T1a) using CT and MRI before and after TURBT.

| Investigation pre TURBT (n = 93) | Investigation post TURBT (n = 143) |
|----------------------------------|------------------------------------|
| CT (91) MRI (33) | CT (150) MRI (32) |
| True positive | 53 | 21 | 92 | 24 |
| False negative (under staged) | 13 | 3 | False negative (under staged) | 18 | 0 |
| Sensitivity | 0.803 | 0.875 | Sensitivity | 0.836 | 1 |
| True negative | 9 | 3 | True negative | 12 | 1 |
| False positive (over staged) | 16 | 6 | False positive (over staged) | 28 | 7 |
| Specificity | 0.36 | 0.33 | Specificity | 0.3 | 0.125 |
| Kappa | 0.169 | 0.233 | Kappa | 0.148 | 0.176 |
| PPV | 0.77 | 0.77 | PPV | 0.76 | 0.77 |
| NPV | 0.41 | 0.5 | NPV | 0.4 | 1 |
| Fishers P (MRI v CT) | 0.66 | 0.66 | Fishers P (MRI v CT) | 0.39 | 0.39 |
| Fishers P | 0.88 | 0.77 | Fishers P TURBT before v after investigation | 0.88 | 0.77 |
| Accuracy | 68% | 73% | Accuracy | 69% | 78% |

Results

There were 91 CT performed pre-TURBT and 150 post-TURBT: for MRI these figures were 33 and 32 respectively. 57 patients had both modalities (Tables 2–4).
The influence of TURBT on staging of bladder cancer

Imaging that states the tumour to be superficial when pathology reveals it to be muscle invasive generates false negatives. This lessens both the specificity and the positive predictive values. Our false positive rate for MRI=77% with a specificity of 0.23 (P = 0.57) and positive predictive value of 0.77 (P = 1.0). CT yields a false positive rate of = 67% with a specificity of 0.33 (P=0.78) and positive predictive value of 0.765 (P = 1.0). None of the values were significant.

Limitations

a. We recognise that this is a selected population representing patients with high grade, initially superficial, cancers that have relapsed. We note that they have had variable intra vesical chemotherapy regimens and systemic neo-adjuvant treatments. Further, we appreciate the MRI numbers are low.

b. The department made a decision to do MRI in a select group of patients whose tumours were larger and seemed to be invasive by the person doing the initial flexible cystoscopy. There were a number of different radiologists reporting the scans. Improvements will be probably be shown with dedicated radiologists and improved technology (multi parametric MRI).

Conclusion

Our results, based on retrospective analysis, suggest that whether one uses imaging for staging pre or post TURBT, it does not influence eventual final staging. However, we accept the limitation of individual variation of reporting and the retrospective nature with a small sample size. The CT scan is now an integral part of initial imaging of hematuria investigation in the western world and newer advances in technology have improved its value and it is as good as MRI for local staging. Therefore the role of MRI is limited unless CT imaging is contraindicated.

Acknowledgments

None.

Conflicts of interest

The authors declared there is no conflict of interest.

References

1. Bladder Cancer Lyon, France: WHO; 2014.
2. Ploeg M, Aben KH, Kiemeney L. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3):289–293.
3. CRUK Cancerstats-Bladder Cancer 2014. Bladder cancer mortality and incidence rates.
4. Bouhelouache K, Turkbey B, Choyke PL. PET/CT and MRI in Bladder Cancer. J Cancer Sci Ther. 2012;5(14(1).
5. Bryan RT, Kirby R, O’Brien T, Mostafid H. So much cost, such little progress. European urology. 2014;66(2):263–264.
6. Kaplan AL, Litwin MS, Chami K. The future of bladder cancer care in the USA. Nat Rev Urol. 2014;11(1):59–62.
7. Bryan RT, Zeegers MP, van Roekel EH, et al. A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. BJU Int. 2013;112(2):169–175.
8. Boustead GB, Fowler S, Swamy R, et al. Section of Oncology B. Stage, grade and pathological characteristics of bladder cancer in the UK:
10.15406/unoaj.2019.07.00235

Citation:
10.15406/unoaj.2019.07.00235

The influence of TURBT on staging of bladder cancer.

The influence of TURBT on staging of bladder cancer: update 2013. Eur Urol. 2013;64(4):639–653.

10.15406/unoaj.2019.07.00235

Citation:
10.15406/unoaj.2019.07.00235

The influence of TURBT on staging of bladder cancer.

Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639–653.

Mowatt G, Zhu S, Kilonzo M, et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010;14(4):1–331.

Zhang J, Gerst S, Lefkowitz RA, et al. Imaging of bladder cancer. Radiol Clin North Am. 2007;45(1):183–205.

Robinson S, Bryan R, Maudgil D, et al. The timing of TURBT and accuracy of bladder cancer staging. European urology supplements. 2016;15(3):e399–e400.

Robinson S, Farooq A, Laniado M, et al. A comparison between computerised tomography and magnetic resonance imaging in the primary staging of bladder cancer as compared to the final histology. Journal of clinical urology. 2019;12(19).

Kim B, Semelka RC, Ascher SM, et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology. 1994;193(1):239–245.

Verma S, Rajesh A, Prasad SR, et al. Urinary bladder cancer: role of MR imaging. Radiographics. 2012;32(2):371–87.

Kumar A, Pond GR, Mukherjee SD, et al. Accuracy of computerised tomography (CT) imaging in predicting pathological stage for patients undergoing surgery for transitional cell carcinoma (TCC) of the bladder. Journal of clinical urology. 2010;28(15):e151–11.

Caterino M, Giunta S, Finocchi V, et al. Primary cancer of the urinary bladder: CT evaluation of the T parameter with different techniques. Abdom Imaging. 2001;26(4):433–438.

Wang LJ, Wong YC, NgKF, et al. Tumor characteristics of urothelial carcinoma on multidetector computerized tomography urography. J Urol. 2010;183(6):2154–2160.

Martignone P, Stacul F, Cavallaro M, et al. 64-Slice CT urography: 30 months of clinical experience. Radiol Med. 2010;115(6):920–935.

Barentz J, Jager G, Wijts J, et al. Primary staging of bladder carcinoma: the role of MRI and a comparison with CT. Eur Urol. 1996;62(2):129–133.

CowenN, Crew J. Imaging bladder cancer. Current opinions in urology. 2010;20(5):409–413.

Beyersdorff D, Zhang J, Schöder H, et al. Bladder cancer: can imaging change patient management? Curr Opin Urol. 2008;18(1):98–104.

Takeuchi M, Sasaki S, Naiki T, et al. MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging. J Magn Reson Imaging. 2013;38(6):1299–309.

El-Assmy A, Abou-El-Gharet ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol. 2009;19(7):1575–1581.

Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging: accuracy for diagnosing T stage and estimating histologic grade. Radiology. 2009;251(1):112–121.

Tekes A, Kamel I, Imam K, et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol. 2005;184(1):121–127.

Papalia R, Simone G, Grasso R, et al. Diffusion weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases. BJU Int. 2012;109(7):1031.

Rosenkrantz AB, Haghhi M, Horn J, et al. Utility of quantitative MRI metrics for assessment of stage and grade of urothelial carcinoma of the bladder: preliminary results. AJR American Journal of Roentgenology. 2013;201(6):1254–1259.

Donaldson SB, Bonington SC, Kershaw LE, et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol. 2013;82(12):2161–2168.

Narumi Y, Kadota T, Ioue E, et al. Bladder tumours: staging with gadolinium-enhanced oblique MR imaging. Radiology. 1993;187(1):145–150.

Swinnen G, Maes A, Potteel H, et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol. 2010;57(4):641–647.

Maurer T, Sousvatzaglou M, Kubler H, et al. Diagnostic efficacy of [11C] choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy. Eur Urol. 2012;61(5):1031–1038.

Vargas HA, Akin O, Schoeder H, et al. Prospective evaluation of MRI, (1) (1)C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol. 2012;81(12):4131–4137.

Rajesh A, Sokhi HK, Fung R, et al. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol. 2011;66(12):1140–1145.

Kalkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010;57(1):60–70.

Rosenkrantz AB, Mussi TC, Melamed J, et al. Bladder cancer: utility of MRI in detection of occult muscle-invasive disease. Acta Radiol. 2012;53(6):695–699.

Engilbertsson H, Aaltosen KE, Björnsson S, et al. Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol. 2015;193(1):53–57.

Mahmud SM, Fong B, Fahmy N, et al. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol. 2006;175(1):78–83.

Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol. 2006;50(6):1176–82.